Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis [Short communication]
Authors:
- 1 February 2012
- journal article
- research article
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 16 (2) , 203-205
Abstract
Following the World Health Organization's endorsement of the Xpert® MTB/RIF assay, which rapidly and simultaneously diagnoses tuberculosis (TB) and detects resistance to rifampin (RMP), the question arises to what extent RMP resistance is an adequate marker for multidrug-resistant TB (MDR-TB). A retrospective analysis of data from >81 countries and subnational settings demonstrated that >40% of RMP-resistant isolates from new TB cases did not display resistance to isoniazid (INH) in settings with relatively low MDR-TB prevalence (one third of all countries and subnational settings). Results indicated the need for INH susceptibility testing in addition to RMP susceptibility testing.Keywords
This publication has 2 references indexed in Scilit:
- Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation studyThe Lancet, 2011
- Rapid Molecular Detection of Tuberculosis and Rifampin ResistanceNew England Journal of Medicine, 2010